These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19161445)

  • 1. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL; Huurman VA; Hilbrands R; Gillard P; Duinkerken G; van der Meer-Prins PW; Versteeg-van der Voort Maarschalk MF; Mathieu C; Keymeulen B; Pipeleers DG; Roep BO; Claas FH
    Clin Exp Immunol; 2009 Apr; 156(1):141-8. PubMed ID: 19161445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.
    Huurman VA; Hilbrands R; Pinkse GG; Gillard P; Duinkerken G; van de Linde P; van der Meer-Prins PM; Versteeg-van der Voort Maarschalk MF; Verbeeck K; Alizadeh BZ; Mathieu C; Gorus FK; Roelen DL; Claas FH; Keymeulen B; Pipeleers DG; Roep BO
    PLoS One; 2008 Jun; 3(6):e2435. PubMed ID: 18560516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.
    Huurman VA; van der Torren CR; Gillard P; Hilbrands R; van der Meer-Prins EP; Duinkerken G; Gorus FK; Claas FH; Keymeulen B; Roelen DL; Pipeleers DG; Roep BO
    Clin Exp Immunol; 2012 Aug; 169(2):190-8. PubMed ID: 22774994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
    Hilbrands R; Huurman VA; Gillard P; Velthuis JH; De Waele M; Mathieu C; Kaufman L; Pipeleers-Marichal M; Ling Z; Movahedi B; Jacobs-Tulleneers-Thevissen D; Monbaliu D; Ysebaert D; Gorus FK; Roep BO; Pipeleers DG; Keymeulen B
    Diabetes; 2009 Oct; 58(10):2267-76. PubMed ID: 19602536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients.
    van Kampen CA; van de Linde P; Duinkerken G; van Schip JJ; Roelen DL; Keymeulen B; Pipeleers DG; Claas FH; Roep BO
    Transplantation; 2005 Jul; 80(1):118-26. PubMed ID: 16003242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.
    Roep BO; Stobbe I; Duinkerken G; van Rood JJ; Lernmark A; Keymeulen B; Pipeleers D; Claas FH; de Vries RR
    Diabetes; 1999 Mar; 48(3):484-90. PubMed ID: 10078547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
    Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
    Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression.
    Nijhoff MF; Engelse MA; Dubbeld J; Braat AE; Ringers J; Roelen DL; van Erkel AR; Spijker HS; Bouwsma H; van der Boog PJ; de Fijter JW; Rabelink TJ; de Koning EJ
    Am J Transplant; 2016 Jan; 16(1):246-53. PubMed ID: 26288226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes.
    O'Connell PJ; Holmes-Walker DJ; Goodman D; Hawthorne WJ; Loudovaris T; Gunton JE; Thomas HE; Grey ST; Drogemuller CJ; Ward GM; Torpy DJ; Coates PT; Kay TW;
    Am J Transplant; 2013 Jul; 13(7):1850-8. PubMed ID: 23668890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
    N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation.
    Du CY; Xu EK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
    Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
    Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation.
    Campbell PM; Salam A; Ryan EA; Senior P; Paty BW; Bigam D; McCready T; Halpin A; Imes S; Al Saif F; Lakey JR; Shapiro AM
    Am J Transplant; 2007 May; 7(5):1242-8. PubMed ID: 17456201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
    Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
    Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients.
    Socci C; Orsenigo E; Santagostino I; Caumo A; Caldara R; Parolini D; Aldrighetti L; Castoldi R; Frasson M; Carvello M; Ghirardelli L; Secchi A; Di Carlo V; Staudacher C
    Transplant Proc; 2010; 42(6):2068-70. PubMed ID: 20692410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of neurotoxicity and beta-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF.
    Froud T; Baidal DA; Ponte G; Ferreira JV; Ricordi C; Alejandro R
    Cell Transplant; 2006; 15(7):613-20. PubMed ID: 17176613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.